CCXAP affirms Taizhou Huaxin Pharmaceutical Investment Co., Ltd’s long-term credit rating at BBBg-, with stable outlook | News & Events | China Chengxin (Asia Pacific) Credit Ratings Company Limited

2022.9.30

CCXAP affirms Taizhou Huaxin Pharmaceutical Investment Co., Ltd’s long-term credit rating at BBBg-, with stable outlook

Hong Kong, 30 September 2022 -- China Chengxin (Asia Pacific) Credit Ratings Company Limited (“CCXAP”) has affirmed Taizhou Huaxin Pharmaceutical Investment Co., Ltd’s long-term credit rating at BBB_g-, with stable outlook.

Click HERE to download the press release.

CCXAP’s public ratings are available at www.ccxap.com (Rating Results) and may be distributed through media and other means. Methodology used in this rating is the Rating Methodology for China’s Local Infrastructure Investment and Financing Companies dated July 2022, available at www.ccxap.com (Rating Methodologies).